All Articles

Although rare cancers affect few people, collectively they impact hundreds of thousands of Americans annually, often leaving patients in a diagnostic limbo due to limited research and expertise. Patient-centric, collaborative navigation approaches are key to shedding light on these overlooked conditions, potentially transforming the landscape of rare cancer diagnosis, treatment, and survivorship for the better.

Navigating Rare Cancer Journeys: Empowering Patients, Building Stronger Healthcare Systems

By Pam Rattananont, MPH

Rare Cancers

February 2025 Vol 16, No 2

Rare diseases often come with an invisible burden—years of searching for answers, countless doctors who dismiss or misdiagnose their symptoms, and the emotional toll of navigating a healthcare system unequipped for their needs.

TRACER Initiative Targets Rare Cancers

By Diane Mapes; Sabrina Richards

Rare Cancers

February 2025 Vol 16, No 2

Experts at the Fred Hutchinson Cancer Center have created a drug-matching platform to help narrow down additional uses for drugs that have already been investigated and FDA approved.

Enhancing Sustainability in Patient Navigation Programs: Perspectives From the Field

By Linda Fleisher, PhD, MPH; Elsa S. Staples, MPH; Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN; Michelle Chappell, MS; Westley Lighthall, MPH; Andrea J. Dwyer, BS

Navigation

February 2025 Vol 16, No 2

Over the past few decades, many collaborative initiatives have been launched to ensure the professionalization of oncology navigation. With all these advances, the stability and sustainability of these programs are now the focal point and critical to move the field forward.

Sustainability Planning for Patient Navigation: Best Practices

By Elsa S. Staples, MPH; Andrea J. Dwyer, BS

Navigation

February 2025 Vol 16, No 2

This accompaniment to the preceding article offers up best practice tips you can employ on your journey toward funding stability, a key element that contributes to positioning programs and practices for long-term success.

Guiding Lights: The Critical Role of Navigators in Neuro-Oncology

By Cassie Latino, MSN, RN, ONN-CG

Neuro-oncology

February 2025 Vol 16, No 2

“My hope as you read this is for you to gain a better understanding of the complex field of neuro-oncology navigation and to be reminded of simple tools you can use to support patients facing an unsolicited journey with a brain or spinal tumor,” writes Cassie Latino, MSN, RN, ONN-CG, who sheds light on the neuro-oncology navigator’s role as an advocate, educator, and crucial member of the multidisciplinary care team.

Pirtobrutinib in Pretreated Patients With CLL/SLL: Applying Lessons From Clinical Trials to Clinical Practice

Clinical Trials

Special Issues and Supplements

In their expert commentaries, Katherine Tobon, PharmD, BCOP, and Jiajoyce Richardson, DNP, CRNP, examine the role of Bruton tyrosine kinase (BTK) inhibitors, with a particular emphasis on pirtobrutinib, in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). They provide a thorough review of the BRUIN study, concentrating on the safety profile and therapeutic efficacy of pirtobrutinib in patients with CLL or SLL who have previously received at least 1 BTK inhibitor.

The Impact of Numbers, Metrics, and Value

By Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN

The Editor’s Take

January 2025 Vol 16, No 1

Along with survivor mentors are other caring individuals who desire to make a positive impact by volunteering to support people with cancer; this year, you can become an advocate, too!

Reflecting on Progress: Novel FDA Approvals in Oncology Across 2024

FDA Updates

January 2025 Vol 16, No 1

A look back at all the novel approvals in oncology made by the FDA in 2024.

Oral Oncolytic Therapy and the Oncology Nurse Navigator: Maximizing Patient Education and Follow-Up

By Laura A. Johnson, DNP, MSN, APRN, AGCNS-BC, BMTCN; Mary Rodts, DNP, CNP, ONC, FAAN

Original Research

January 2025 Vol 16, No 1

Oncology nurse navigator involvement in the management of patients receiving oral oncolytic therapy can increase the quality of patient care by advancing patient understanding of their medication, limiting side effects, and improving adherence.

All Articles

Page 12 of 281

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.